V5Z Stock Overview
An RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Sirnaomics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.40 |
| 52 Week High | HK$3.48 |
| 52 Week Low | HK$0.28 |
| Beta | -0.27 |
| 1 Month Change | 32.24% |
| 3 Month Change | 24.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| V5Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -2.9% | -2.6% |
| 1Y | n/a | -14.7% | 6.9% |
Return vs Industry: Insufficient data to determine how V5Z performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how V5Z performed against the German Market.
Price Volatility
| V5Z volatility | |
|---|---|
| V5Z Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V5Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: V5Z's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 90 | Hung Fai Poon | www.sirnaomics.com |
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors.
Sirnaomics Ltd. Fundamentals Summary
| V5Z fundamental statistics | |
|---|---|
| Market cap | €36.49m |
| Earnings (TTM) | -€78.39m |
| Revenue (TTM) | €1.03m |
35.3x
P/S Ratio-0.5x
P/E RatioIs V5Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V5Z income statement (TTM) | |
|---|---|
| Revenue | US$1.08m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.08m |
| Other Expenses | US$82.88m |
| Earnings | -US$81.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 100.00% |
| Net Profit Margin | -7,587.85% |
| Debt/Equity Ratio | -2.4% |
How did V5Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sirnaomics Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| LINDA SHU | HSBC |